Table 5. . OS, PFS and TTP.
| TACE-B | TACE | TACE + B (WT) | TACE + B (mut) | TACE (WT) | TACE (mut) | p-value (TACE + B vs TACE) | p-value (TACE + B WT vs mut) | p-value (TACE WT vs mut) | p-value (TACE + B WT vs TACE WT) | p-value (TACE + B mut vs TACE mut) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OS from metastasis diagnosis | 18 (7–26) | 15.8 (5–52) | 14.5 (12–33) | 19 (7–26) | 27.7 (9–52.73) | 15.03 (13.1–21.2) | 0.25 | 0.348499 | 0.111447 | 0.309137 | 0.048317† |
| TTP | 10 (3–15) | 2.08 (1.03–11) | 8 (3–24) | 10 (3–24) | 5.06 (1.3–9) | 1.7 (1.1–8) | <0.001† | 0.399375 | 0.215221 | 0.013926† | <0.001† |
| PFS | 13 (3–24) | 11.15 (4–51) | 12 (3–28) | 14 (3–24) | 22.63 (3–51.4) | 10.83 (3.8–23) | 0.3123 | 0.295387 | 0.222201 | 0.226051 | 0.280808 |
| OS from primitive tumor | 21.73 (13.5–27) | 27.8 (3–58) | 13.53 (4–23) | 23.7 (9–52) | 32.26 (15.5–58) | 25.76 (12.1–61) | 0.09 | 0.222201 | 0.127852 | 0.127852 | 0.284394 |
†
p < 0.05.
B: Bevacizumab; mut: Mutated; OS: Overall survival; PFS: Progression-free survival; TACE: Transarterial chemoembolization; TTP: Time to progression; WT: Wild-type.